World PulseNow
Newsletter

Palisade Bio begins dosing in fibrostenotic Crohn's disease study

Investing.com•Monday, October 20, 2025 at 12:52:52 PM
PositiveFinancial Markets
Palisade Bio begins dosing in fibrostenotic Crohn's disease study
Palisade Bio has initiated dosing in a clinical trial focused on fibrostenotic Crohn's disease, a significant step for patients suffering from this challenging condition. This study aims to evaluate the effectiveness of a new treatment, which could potentially improve the quality of life for many individuals affected by Crohn's disease. The advancement in research and treatment options is crucial, as it brings hope to those who have limited choices.
— Curated by the World Pulse Now AI Editorial System
Read Original

Was this article worth reading? Share it

Recommended Readings
Palisade Bio shareholders approve director elections and reverse stock split option
Investing.coman hour ago
Palisade Bio shareholders approve director elections and reverse stock split option
PositiveFinancial Markets
Palisade Bio has received approval from its shareholders for the election of directors and the option for a reverse stock split. This decision is significant as it reflects the confidence of shareholders in the company's leadership and strategic direction. The reverse stock split could enhance the company's stock price and attract more investors, which is crucial for its growth and stability in the competitive biotech industry.
Read full article
via Investing.com
Zanzalintinib-atezolizumab combo shows survival benefit in colorectal cancer
Investing.com16 hours ago
Zanzalintinib-atezolizumab combo shows survival benefit in colorectal cancer
PositiveFinancial Markets
A recent clinical trial has shown that the combination of zanzalintinib and atezolizumab offers significant survival benefits for patients with colorectal cancer. This finding is crucial as it opens new avenues for treatment, potentially improving outcomes for many individuals battling this challenging disease.
Read full article
via Investing.com
IO Biotech's melanoma vaccine combination narrowly misses primary endpoint
Investing.com16 hours ago
IO Biotech's melanoma vaccine combination narrowly misses primary endpoint
NegativeFinancial Markets
IO Biotech's recent clinical trial for its melanoma vaccine combination has narrowly missed its primary endpoint, raising concerns about the treatment's effectiveness. This outcome is significant as it highlights the challenges in developing successful cancer therapies and may impact future research and investment in similar treatments.
Read full article
via Investing.com
Kelun-Biotech's lung cancer drug shows improved survival in trial
Investing.com21 hours ago
Kelun-Biotech's lung cancer drug shows improved survival in trial
PositiveFinancial Markets
Kelun-Biotech has announced promising results from a clinical trial of its lung cancer drug, which has shown improved survival rates for patients. This breakthrough is significant as lung cancer remains one of the leading causes of cancer-related deaths worldwide. The positive outcomes from this trial could lead to new treatment options for patients, potentially changing the landscape of lung cancer therapy.
Read full article
via Investing.com
Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial
Investing.coma day ago
Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial
PositiveFinancial Markets
A recent clinical trial for raludotatug, a new treatment for ovarian cancer, has shown a promising 50.5% response rate. This is significant as it highlights potential advancements in the fight against a disease that affects many women worldwide. The results could lead to more effective treatment options and improved outcomes for patients, making this development a hopeful step forward in cancer research.
Read full article
via Investing.com
Pancreatic cancer drug shows 41% response rate in clinical trial
Investing.com2 days ago
Pancreatic cancer drug shows 41% response rate in clinical trial
PositiveFinancial Markets
A new drug for pancreatic cancer has demonstrated a promising 41% response rate in recent clinical trials, offering hope to patients battling this aggressive disease. This significant finding could lead to improved treatment options and better outcomes for those affected, highlighting the ongoing advancements in cancer research and the potential for new therapies to change lives.
Read full article
via Investing.com
ENHERTU shows 92% invasive disease-free survival rate at three years in breast cancer trial
Investing.com2 days ago
ENHERTU shows 92% invasive disease-free survival rate at three years in breast cancer trial
PositiveFinancial Markets
A recent clinical trial has shown that ENHERTU, a targeted therapy for breast cancer, achieved an impressive 92% invasive disease-free survival rate at three years. This significant result highlights the potential of ENHERTU to improve outcomes for patients battling this challenging disease, offering hope for better treatment options in oncology.
Read full article
via Investing.com
ESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer
Investing.com2 days ago
ESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer
PositiveFinancial Markets
At the ESMO 2025 conference, the drug Enhertu has demonstrated the highest pathologic complete response (pCR) rate in patients with HER2-positive early breast cancer. This is significant as it highlights a promising advancement in treatment options for a challenging subtype of breast cancer, potentially improving outcomes for many patients.
Read full article
via Investing.com
Latest from Financial Markets
Dakota Gold director O’Rourke sells $738k in shares
Investing.coman hour ago
Dakota Gold director O’Rourke sells $738k in shares
NeutralFinancial Markets
Dakota Gold's director, O’Rourke, has sold shares worth $738,000, which raises questions about the company's future direction. While such transactions are common in the corporate world, they can signal shifts in confidence or strategy. Investors will be watching closely to see how this impacts Dakota Gold's performance and market perception.
Read full article
via Investing.com
RBB Bancorp reports 8.7% increase in quarterly net income
Investing.coman hour ago
RBB Bancorp reports 8.7% increase in quarterly net income
PositiveFinancial Markets
RBB Bancorp has reported an impressive 8.7% increase in its quarterly net income, showcasing the company's strong financial performance. This growth is significant as it reflects the bank's effective strategies and resilience in a competitive market, which can boost investor confidence and potentially lead to further investments.
Read full article
via Investing.com
Earnings call transcript: FRMO Corp Q1 2025 highlights crypto mining strategy
Investing.coman hour ago
Earnings call transcript: FRMO Corp Q1 2025 highlights crypto mining strategy
PositiveFinancial Markets
FRMO Corp's recent earnings call highlighted their innovative strategy in the crypto mining sector for Q1 2025. This approach not only showcases their commitment to staying ahead in the rapidly evolving digital currency landscape but also positions them for potential growth and profitability. Investors and stakeholders should pay attention, as this could signal a significant shift in the company's operations and market presence.
Read full article
via Investing.com
Rocket Lab stock rises ahead of upcoming iQPS satellite launch
Investing.coman hour ago
Rocket Lab stock rises ahead of upcoming iQPS satellite launch
PositiveFinancial Markets
Rocket Lab's stock is experiencing a positive surge as the company prepares for its upcoming iQPS satellite launch. This event is significant not only for Rocket Lab but also for the satellite industry, as it showcases the company's growing capabilities and potential for future contracts. Investors are optimistic about the launch's success, which could lead to increased demand for Rocket Lab's services and further bolster its market position.
Read full article
via Investing.com
Dragonfly Energy restructures term loan and issues Series B preferred stock
Investing.coman hour ago
Dragonfly Energy restructures term loan and issues Series B preferred stock
PositiveFinancial Markets
Dragonfly Energy has successfully restructured its term loan and issued Series B preferred stock, marking a significant step in its financial strategy. This move not only strengthens the company's balance sheet but also positions it for future growth in the energy sector. Investors are likely to view this positively, as it demonstrates the company's commitment to enhancing its capital structure and expanding its operations.
Read full article
via Investing.com
Bayview Acquisition Corp makes $100,000 extension payment to trust account
Investing.coman hour ago
Bayview Acquisition Corp makes $100,000 extension payment to trust account
PositiveFinancial Markets
Bayview Acquisition Corp has made a significant $100,000 extension payment to its trust account, ensuring the continuation of its operations and potential future investments. This move is crucial as it reflects the company's commitment to maintaining its financial stability and pursuing strategic opportunities in the market.
Read full article
via Investing.com